Keen On NASDAQ Slot, Concentra Looks To Scupper Jounce And Redx Merger

Mystery Firm Makes Last Minute Bid

16 Mar 2023

In February, Jounce’s future looked bleak after the failure of vopratelimab and fears that its finances would run out. Now, it has two suitors with Concentra making a bid to compete with an all-stock merger with the UK’s Redx.

New York — A NASDAQ listing is an attractive proposition • Source: Shutterstock: rblfmr

Less than a month after laying off half its staff and leaping onto a life raft thrown by Redx Pharma Plc, Jounce Therapeutics, Inc. has received a takeover offer from another suitor, little-known Concentra Biosciences.

Things have moved fast since the end of February when Jounce announced a 57% reduction of its workforce after saying...